Clinical trials: Myeloid
Hematologic Malignancies
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or…
- Trial name
- HPDSC (NCT00596999)
- Testing
- UCB and HPDSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML
- Trial name
- TWT-202 (NCT04730258)
- Testing
- CFI-400945, Azacitidine
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Treadwell Therapeutics, Inc
Myeloid Leukemia
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
This study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (CML) used in a real world clinical practice setting.
- Trial name
- NCT05363488
- Testing
- Bosutinib
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
The purpose of this study is to determine if giving tipifarnib after standard treatment will prevent leukemia from coming back (relapsing). Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI).
- Trial name
- NCT00048503
- Testing
- ZARNESTRA, tipifarnib, R115777
- Volunteers
- 88 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hematological Malignancy
KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
- Trial name
- NCT07873827
- Testing
- MEN2312
- Volunteers
- 115 people
- Sponsor
- Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
The purpose of this observational study is to assess the real-world safety of maintenance therapy with oral azacitidine in Korean participants with acute myeloid leukemia (AML) who achieved first complete remission (CR) or…
- Trial name
- NCT06073769
- Testing
- Oral azacitidine
- Where
- 2 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Acute
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).
- Trial name
- NCT04336982
- Testing
- CC-90009, Venetoclax, Azacitidine
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Celgene
Leukemia, Myeloid
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study
- Conditions
- Leukemia, Myeloid, Acute
- Trial name
- NCT07123662
- Testing
- Gamma-Delta T cell injection, Standard prophylactic treatment
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
The purpose of this study is to confirm the safety and tolerability of oral panobinostat (PAN) in combination with a fixed dose of 5-Azacitidine (5-Aza) in adult Japanese patients with Myelodysplastic Syndromes (MDS), Chronic…
- Conditions
- Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)
- Trial name
- NCT01613976
- Testing
- Panobinostat
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
The primary objective of this study is to estimate the major cytogenetic response (MCyR) rate to Dasatinib in subjects with CP CML, complete and overall hematologic response (CHR and OHR) rate in subjects with AD CML or Ph+ ALL…
- Trial name
- NCT00529763
- Testing
- Dasatinib
- Where
- 14 sites in China
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
The purpose of this study is to evaluate Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
- Trial name
- CARCML (NCT05282108)
- Testing
- Carcemia, Glivec
- Where
- 4 sites in Egypt
- Volunteers
- 240 people
- Sponsor
- Hikma Pharmaceuticals LLC
Leukemia, Lymphoma
Study of @neWorld: A Virtual Community for Children With Cancer
RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-to-read medical information, and chat with family members, medical staff…
- Conditions
- Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00070421
- Testing
- complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Sponsor
- Leap of Faith Technologies
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
The objectives of Part 1 of the study were: To determine the rate of hematologic response (HR) lasting ≥4 weeks in participants with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the accelerated phase…
- Conditions
- Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00171249
- Testing
- STI571 400 mg, STI571 600 mg
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Acute
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are…
- Trial name
- NCT04241549
- Testing
- Cusatuzumab, Azacitidine
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- OncoVerity, Inc.
Acute Myeloid Leukemia
A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding…
- Trial name
- REVIVE (NCT03987958)
- Where
- 12 sites in Israel
- Volunteers
- 100 people
- Sponsor
- AbbVie
Acute Myeloid Leukaemia
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
- Trial name
- NCT07036250
- Testing
- U32 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
FLT3-mutated Acute Myeloid Leukemia
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia.
- Trial name
- NCT03591510
- Testing
- Midostaurin, Fludarabine, Cytarabine
- Where
- 15 sites in Czechia, Germany and 8 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.
- Trial name
- NCT02511340
- Testing
- Flumatinib mesylate tablet 600 mg qd
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Study CR-AIR-006 is a part of the ATIR clinical development plan and will provide control data for patients treated with ATIR in clinical studies (e.g. study CR-AIR-007).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02188290
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 178 people
- Sponsor
- Kiadis Pharma
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome…
- Trial name
- NCT00349518
- Testing
- Dasatinib
- Where
- 20 sites in Hungary, Italy and 4 more
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.